PMC:7386875 / 30802-31727 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T286","span":{"begin":27,"end":31},"obj":"Body_part"},{"id":"T287","span":{"begin":43,"end":52},"obj":"Body_part"},{"id":"T288","span":{"begin":68,"end":72},"obj":"Body_part"},{"id":"T289","span":{"begin":73,"end":87},"obj":"Body_part"},{"id":"T290","span":{"begin":89,"end":91},"obj":"Body_part"},{"id":"T291","span":{"begin":254,"end":266},"obj":"Body_part"},{"id":"T292","span":{"begin":267,"end":270},"obj":"Body_part"},{"id":"T293","span":{"begin":726,"end":735},"obj":"Body_part"},{"id":"T294","span":{"begin":853,"end":858},"obj":"Body_part"}],"attributes":[{"id":"A286","pred":"fma_id","subj":"T286","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A287","pred":"fma_id","subj":"T287","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A288","pred":"fma_id","subj":"T288","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A289","pred":"fma_id","subj":"T289","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A290","pred":"fma_id","subj":"T290","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A291","pred":"fma_id","subj":"T291","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A292","pred":"fma_id","subj":"T292","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A293","pred":"fma_id","subj":"T293","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A294","pred":"fma_id","subj":"T294","obj":"http://purl.org/sig/ont/fma/fma67498"}],"text":"In addition to mediating T-cell functions, platelets can increase B-cell immunoglobulin (Ig)G1, IgG2, and IgG3 production.90 This is potentially significant in the setting of COVID-19 since the development of antiphospholipid antibodies, such as anti-β2 glycoprotein IgG antibodies, have been described in association with thrombosis in patients with COVID-19.91 In addition, a cohort study from France describes a large percentage of patients with severe COVID-19 demonstrate a detectable lupus anticoagulant.27 However, whether the presence of antiphospholipid antibodies in COVID-19 plays a role in COVID-19-associated thrombosis or represents merely an association remains to be established. Nevertheless, delineating how platelets modulate the adaptive immune response to SARS-CoV-2 and the role adaptive immunity plays in mediating thrombosis and organ injury will be crucial in uncovering novel therapeutic strategies."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T51","span":{"begin":853,"end":858},"obj":"Body_part"}],"attributes":[{"id":"A51","pred":"uberon_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"In addition to mediating T-cell functions, platelets can increase B-cell immunoglobulin (Ig)G1, IgG2, and IgG3 production.90 This is potentially significant in the setting of COVID-19 since the development of antiphospholipid antibodies, such as anti-β2 glycoprotein IgG antibodies, have been described in association with thrombosis in patients with COVID-19.91 In addition, a cohort study from France describes a large percentage of patients with severe COVID-19 demonstrate a detectable lupus anticoagulant.27 However, whether the presence of antiphospholipid antibodies in COVID-19 plays a role in COVID-19-associated thrombosis or represents merely an association remains to be established. Nevertheless, delineating how platelets modulate the adaptive immune response to SARS-CoV-2 and the role adaptive immunity plays in mediating thrombosis and organ injury will be crucial in uncovering novel therapeutic strategies."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T250","span":{"begin":175,"end":183},"obj":"Disease"},{"id":"T251","span":{"begin":323,"end":333},"obj":"Disease"},{"id":"T252","span":{"begin":456,"end":464},"obj":"Disease"},{"id":"T253","span":{"begin":490,"end":495},"obj":"Disease"},{"id":"T254","span":{"begin":577,"end":585},"obj":"Disease"},{"id":"T255","span":{"begin":602,"end":610},"obj":"Disease"},{"id":"T256","span":{"begin":622,"end":632},"obj":"Disease"},{"id":"T257","span":{"begin":777,"end":785},"obj":"Disease"},{"id":"T258","span":{"begin":838,"end":848},"obj":"Disease"},{"id":"T259","span":{"begin":859,"end":865},"obj":"Disease"}],"attributes":[{"id":"A250","pred":"mondo_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A251","pred":"mondo_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A252","pred":"mondo_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A253","pred":"mondo_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/MONDO_0004670"},{"id":"A254","pred":"mondo_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A255","pred":"mondo_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A256","pred":"mondo_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A257","pred":"mondo_id","subj":"T257","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A258","pred":"mondo_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A259","pred":"mondo_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"In addition to mediating T-cell functions, platelets can increase B-cell immunoglobulin (Ig)G1, IgG2, and IgG3 production.90 This is potentially significant in the setting of COVID-19 since the development of antiphospholipid antibodies, such as anti-β2 glycoprotein IgG antibodies, have been described in association with thrombosis in patients with COVID-19.91 In addition, a cohort study from France describes a large percentage of patients with severe COVID-19 demonstrate a detectable lupus anticoagulant.27 However, whether the presence of antiphospholipid antibodies in COVID-19 plays a role in COVID-19-associated thrombosis or represents merely an association remains to be established. Nevertheless, delineating how platelets modulate the adaptive immune response to SARS-CoV-2 and the role adaptive immunity plays in mediating thrombosis and organ injury will be crucial in uncovering novel therapeutic strategies."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T299","span":{"begin":25,"end":31},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T300","span":{"begin":66,"end":72},"obj":"http://purl.obolibrary.org/obo/CL_0000236"},{"id":"T301","span":{"begin":376,"end":377},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T302","span":{"begin":413,"end":414},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T303","span":{"begin":477,"end":478},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T304","span":{"begin":510,"end":512},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T305","span":{"begin":592,"end":593},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T306","span":{"begin":853,"end":858},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"}],"text":"In addition to mediating T-cell functions, platelets can increase B-cell immunoglobulin (Ig)G1, IgG2, and IgG3 production.90 This is potentially significant in the setting of COVID-19 since the development of antiphospholipid antibodies, such as anti-β2 glycoprotein IgG antibodies, have been described in association with thrombosis in patients with COVID-19.91 In addition, a cohort study from France describes a large percentage of patients with severe COVID-19 demonstrate a detectable lupus anticoagulant.27 However, whether the presence of antiphospholipid antibodies in COVID-19 plays a role in COVID-19-associated thrombosis or represents merely an association remains to be established. Nevertheless, delineating how platelets modulate the adaptive immune response to SARS-CoV-2 and the role adaptive immunity plays in mediating thrombosis and organ injury will be crucial in uncovering novel therapeutic strategies."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T146","span":{"begin":254,"end":266},"obj":"Chemical"},{"id":"T147","span":{"begin":496,"end":509},"obj":"Chemical"}],"attributes":[{"id":"A146","pred":"chebi_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A147","pred":"chebi_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/CHEBI_50249"}],"text":"In addition to mediating T-cell functions, platelets can increase B-cell immunoglobulin (Ig)G1, IgG2, and IgG3 production.90 This is potentially significant in the setting of COVID-19 since the development of antiphospholipid antibodies, such as anti-β2 glycoprotein IgG antibodies, have been described in association with thrombosis in patients with COVID-19.91 In addition, a cohort study from France describes a large percentage of patients with severe COVID-19 demonstrate a detectable lupus anticoagulant.27 However, whether the presence of antiphospholipid antibodies in COVID-19 plays a role in COVID-19-associated thrombosis or represents merely an association remains to be established. Nevertheless, delineating how platelets modulate the adaptive immune response to SARS-CoV-2 and the role adaptive immunity plays in mediating thrombosis and organ injury will be crucial in uncovering novel therapeutic strategies."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T49","span":{"begin":209,"end":236},"obj":"Phenotype"},{"id":"T50","span":{"begin":490,"end":509},"obj":"Phenotype"},{"id":"T51","span":{"begin":546,"end":573},"obj":"Phenotype"}],"attributes":[{"id":"A49","pred":"hp_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/HP_0003613"},{"id":"A50","pred":"hp_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/HP_0025343"},{"id":"A51","pred":"hp_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/HP_0003613"}],"text":"In addition to mediating T-cell functions, platelets can increase B-cell immunoglobulin (Ig)G1, IgG2, and IgG3 production.90 This is potentially significant in the setting of COVID-19 since the development of antiphospholipid antibodies, such as anti-β2 glycoprotein IgG antibodies, have been described in association with thrombosis in patients with COVID-19.91 In addition, a cohort study from France describes a large percentage of patients with severe COVID-19 demonstrate a detectable lupus anticoagulant.27 However, whether the presence of antiphospholipid antibodies in COVID-19 plays a role in COVID-19-associated thrombosis or represents merely an association remains to be established. Nevertheless, delineating how platelets modulate the adaptive immune response to SARS-CoV-2 and the role adaptive immunity plays in mediating thrombosis and organ injury will be crucial in uncovering novel therapeutic strategies."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T83","span":{"begin":749,"end":773},"obj":"http://purl.obolibrary.org/obo/GO_0002250"},{"id":"T84","span":{"begin":758,"end":773},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"In addition to mediating T-cell functions, platelets can increase B-cell immunoglobulin (Ig)G1, IgG2, and IgG3 production.90 This is potentially significant in the setting of COVID-19 since the development of antiphospholipid antibodies, such as anti-β2 glycoprotein IgG antibodies, have been described in association with thrombosis in patients with COVID-19.91 In addition, a cohort study from France describes a large percentage of patients with severe COVID-19 demonstrate a detectable lupus anticoagulant.27 However, whether the presence of antiphospholipid antibodies in COVID-19 plays a role in COVID-19-associated thrombosis or represents merely an association remains to be established. Nevertheless, delineating how platelets modulate the adaptive immune response to SARS-CoV-2 and the role adaptive immunity plays in mediating thrombosis and organ injury will be crucial in uncovering novel therapeutic strategies."}

{"project":"LitCovid-sentences","denotations":[{"id":"T109","span":{"begin":0,"end":695},"obj":"Sentence"},{"id":"T110","span":{"begin":696,"end":925},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In addition to mediating T-cell functions, platelets can increase B-cell immunoglobulin (Ig)G1, IgG2, and IgG3 production.90 This is potentially significant in the setting of COVID-19 since the development of antiphospholipid antibodies, such as anti-β2 glycoprotein IgG antibodies, have been described in association with thrombosis in patients with COVID-19.91 In addition, a cohort study from France describes a large percentage of patients with severe COVID-19 demonstrate a detectable lupus anticoagulant.27 However, whether the presence of antiphospholipid antibodies in COVID-19 plays a role in COVID-19-associated thrombosis or represents merely an association remains to be established. Nevertheless, delineating how platelets modulate the adaptive immune response to SARS-CoV-2 and the role adaptive immunity plays in mediating thrombosis and organ injury will be crucial in uncovering novel therapeutic strategies."}

{"project":"2_test","denotations":[{"id":"32586214-17656005-21597751","span":{"begin":122,"end":124},"obj":"17656005"},{"id":"32586214-32268022-21597752","span":{"begin":360,"end":362},"obj":"32268022"},{"id":"32586214-32367170-21597753","span":{"begin":510,"end":512},"obj":"32367170"}],"text":"In addition to mediating T-cell functions, platelets can increase B-cell immunoglobulin (Ig)G1, IgG2, and IgG3 production.90 This is potentially significant in the setting of COVID-19 since the development of antiphospholipid antibodies, such as anti-β2 glycoprotein IgG antibodies, have been described in association with thrombosis in patients with COVID-19.91 In addition, a cohort study from France describes a large percentage of patients with severe COVID-19 demonstrate a detectable lupus anticoagulant.27 However, whether the presence of antiphospholipid antibodies in COVID-19 plays a role in COVID-19-associated thrombosis or represents merely an association remains to be established. Nevertheless, delineating how platelets modulate the adaptive immune response to SARS-CoV-2 and the role adaptive immunity plays in mediating thrombosis and organ injury will be crucial in uncovering novel therapeutic strategies."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1064","span":{"begin":106,"end":110},"obj":"Gene"},{"id":"1065","span":{"begin":251,"end":253},"obj":"Gene"},{"id":"1066","span":{"begin":337,"end":345},"obj":"Species"},{"id":"1067","span":{"begin":435,"end":443},"obj":"Species"},{"id":"1068","span":{"begin":777,"end":787},"obj":"Species"},{"id":"1069","span":{"begin":175,"end":183},"obj":"Disease"},{"id":"1070","span":{"begin":323,"end":333},"obj":"Disease"},{"id":"1071","span":{"begin":351,"end":359},"obj":"Disease"},{"id":"1072","span":{"begin":456,"end":464},"obj":"Disease"},{"id":"1073","span":{"begin":577,"end":585},"obj":"Disease"},{"id":"1074","span":{"begin":602,"end":610},"obj":"Disease"},{"id":"1075","span":{"begin":622,"end":632},"obj":"Disease"},{"id":"1076","span":{"begin":838,"end":848},"obj":"Disease"},{"id":"1077","span":{"begin":853,"end":865},"obj":"Disease"}],"attributes":[{"id":"A1064","pred":"tao:has_database_id","subj":"1064","obj":"Gene:3502"},{"id":"A1065","pred":"tao:has_database_id","subj":"1065","obj":"Gene:170589"},{"id":"A1066","pred":"tao:has_database_id","subj":"1066","obj":"Tax:9606"},{"id":"A1067","pred":"tao:has_database_id","subj":"1067","obj":"Tax:9606"},{"id":"A1068","pred":"tao:has_database_id","subj":"1068","obj":"Tax:2697049"},{"id":"A1069","pred":"tao:has_database_id","subj":"1069","obj":"MESH:C000657245"},{"id":"A1070","pred":"tao:has_database_id","subj":"1070","obj":"MESH:D013927"},{"id":"A1071","pred":"tao:has_database_id","subj":"1071","obj":"MESH:C000657245"},{"id":"A1072","pred":"tao:has_database_id","subj":"1072","obj":"MESH:C000657245"},{"id":"A1073","pred":"tao:has_database_id","subj":"1073","obj":"MESH:C000657245"},{"id":"A1074","pred":"tao:has_database_id","subj":"1074","obj":"MESH:C000657245"},{"id":"A1075","pred":"tao:has_database_id","subj":"1075","obj":"MESH:D013927"},{"id":"A1076","pred":"tao:has_database_id","subj":"1076","obj":"MESH:D013927"},{"id":"A1077","pred":"tao:has_database_id","subj":"1077","obj":"MESH:D009102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In addition to mediating T-cell functions, platelets can increase B-cell immunoglobulin (Ig)G1, IgG2, and IgG3 production.90 This is potentially significant in the setting of COVID-19 since the development of antiphospholipid antibodies, such as anti-β2 glycoprotein IgG antibodies, have been described in association with thrombosis in patients with COVID-19.91 In addition, a cohort study from France describes a large percentage of patients with severe COVID-19 demonstrate a detectable lupus anticoagulant.27 However, whether the presence of antiphospholipid antibodies in COVID-19 plays a role in COVID-19-associated thrombosis or represents merely an association remains to be established. Nevertheless, delineating how platelets modulate the adaptive immune response to SARS-CoV-2 and the role adaptive immunity plays in mediating thrombosis and organ injury will be crucial in uncovering novel therapeutic strategies."}